The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC).
introduction Liver cancer is the sixth most common cancer worldwide, with estimated 845 582 new cases and 806 873 deaths in 2015 [1] . Hepatocellular carcinoma (HCC), which accounts for the majority of liver cancers, is a highly vascularized tumour. Angiogenesis, via several pathways, including vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signalling, is thought to contribute to pathogenesis of HCC [2] . Multikinase inhibitor sorafenib, which blocks VEGFR kinases among others, has demonstrated improved overall survival (OS) in treatment-naïve patients with advanced HCC in randomized phase III studies [3, 4] . However, no other single-agent kinase inhibitor (e.g. sunitinib, linifanib, brivanib) [5] [6] [7] or combination (e.g. sorafenib/erlotinib) [8] has exceeded clinical benefits of sorafenib in first-line HCC, and sorafenib remains the only approved systemic therapy for advanced HCC. Yet, the efficacy of sorafenib may be short-lived due to toxicities, leading to disease progression following first-line sorafenib. There are currently no effective treatment options for patients who progress on or are intolerant to sorafenib.
Axitinib is a potent and selective inhibitor of VEGFRs 1-3 [9] , approved as second-line therapy for advanced renal cell carcinoma and has shown nonclinical activity in HCC animal models (Pfizer, data on file), providing evidence for its therapeutic potential. Furthermore, safety and pharmacokinetics of axitinib have been determined in patients with mild or moderate hepatic impairment [10] . This phase II trial evaluated the efficacy and safety of axitinib in combination with best supportive care (BSC) compared with placebo plus BSC in patients with advanced HCC previously treated with an antiangiogenic therapy. Additionally, serum proteins known to be involved in angiogenesis and tumour growth were explored as potential baseline biomarkers for axitinib efficacy.
methods study design
This is a randomized, double-blind, global phase II study (ClinicalTrials.gov, NCT01210495). Patients were stratified by tumour invasion (presence versus absence of extrahepatic spread and/or vascular invasion) and geographic region (Asian versus non-Asian sites) and randomly assigned (2:1) to axitinib/BSC or placebo/BSC using a centralized interactive voice response system (IMPALA; supplementary Text, available at Annals of Oncolgy online). The primary end point was OS. Secondary end points included progression-free survival (PFS), time to tumour progression (TTP), objective response rate (ORR), clinical benefit rate (CBR), patient-reported outcomes (PROs), and safety. Prognostic or predictive potential of serum soluble proteins were also investigated.
The study protocol was approved by institutional review boards or independent ethics committees and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines on Good Clinical Practice. Each patient provided informed consent.
patients and treatment
Patients with histologically or cytologically confirmed locally advanced or metastatic HCC, who progressed on or were intolerant [discontinued treatment due to treatment-related grade 3/4 adverse event (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v3.0] to one prior antiangiogenic therapy, were eligible. Other key eligibility criteria included presence of ≥1 measurable lesion, Child-Pugh A liver function, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 (supplementary Text, available at Annals of Oncology online).
Randomized patients received axitinib or placebo orally at a starting dose of 5 mg twice-daily (b.i.d.) in 4-week cycles. Doses could be modified per protocol-specified algorithm (supplementary Text, available at Annals of Oncology online). All patients additionally received BSC. The study team, investigators, and patients were blinded to treatment assignment.
assessments
Baseline tumour assessments included CT or MRI scans, which were repeated every 8 weeks. Tumour response was assessed by investigators according to the Response Evaluation Criteria in Solid Tumours v1.1. Safety was monitored throughout the study and AEs graded per the NCI-CTCAE. Physical examinations and laboratory tests were carried out at baseline, Week 2 and/or 4, and every 4 weeks thereafter. Blood pressure (BP) was monitored at each clinic visit and by patients at home. PROs were assessed using the validated Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary (Hep) questionnaire [11] including Hepatobiliary Symptom Index (FHSI-8) and EuroQol (EQ)-5D, and circulating serum levels of soluble proteins at baseline were measured (supplementary Text, available at Annals of Oncology online).
statistical analyses
The study was designed to detect a hazard ratio (HR) of 0.60 for OS in favour of axitinib/BSC, assuming the median OS of 5.0 months with placebo/BSC and 8.3 months with axitinib/BSC. To detect a statistically significant difference between arms, 150 OS events were needed for a stratified one-sided log-rank test with a significance level of 0.025 and 80% power. Assuming a ∼13-month patient accrual period, 5% dropout rate per arm, and ∼11-month follow-up, 198 patients were required. One predefined interim analysis was carried out (supplementary Text, available at Annals of Oncology online).
Time-to-event end points were analysed using the Kaplan-Meier method and median and two-sided 95% confidence intervals (CIs) were estimated. Comparison between treatment arms was made with stratified or unstratified one-sided log-rank test (α = 0.025), and HR and 95% CI were calculated. A Cox proportional hazards model was used to explore potential influences of baseline patient characteristics on OS. ORR ( proportion of patients with complete or partial response) or CBR ( proportion of patients with complete or partial response or ≥8 weeks stable disease) were compared using a stratified Cochran-Mantel-Haenszel test, and relative risk ratio and two-sided 95% CI were calculated. Statistical analysis methodology for PROs and biomarkers are provided in supplementary Text, available at Annals of Oncology online.
results

patients and treatment
Between December 2010 and July 2012, patients were assigned to axitinib/BSC (n = 134) and placebo/BSC (n = 68) (supplementary Figure S1 , available at Annals of Oncology online). One patient assigned to the axitinib/BSC arm died due to disease progression and did not receive any study treatment and was excluded from safety analyses. The majority of patients were male (82%) and Asian (62%). Baseline patient characteristics were generally comparable between the axitinib/BSC and placebo/BSC arms (Table 1) , although a ≥5% absolute difference was seen with age <65 years (60% versus 53%), hepatitis C (29% versus 16%), and liver cirrhosis (66% versus 60%). Additionally, more patients in the placebo/BSC than axitinib/BSC arm were intolerant to first-line antiangiogenic therapy (25% versus 10%). At data cut-off for the primary analysis (3 March 2014), 113 (84%) axitinib/BSC-treated and 54 (79%) placebo/BSC-treated patients discontinued the study, primarily due to death. The main reasons for treatment discontinuation with axitinib/BSC (n = 127) and placebo/BSC (n = 67), respectively, were objective progression (52% versus 74%) and AEs (23% versus 12%). Patients in the axitinib/BSC arm received study treatment longer than those in the placebo/BSC arm (114.0 versus 57.5 days), but had more dose interruptions (80.5% versus 55.9%) or reductions (44.4% versus 5.9%) and fewer follow-up therapies (33.6% versus 54.4%). This study is ongoing with six patients in the axitinib/BSC arm still on treatment.
efficacy
The difference in OS between the axitinib/BSC-and placebo/ BSC-treated patients did not reach statistical significance (HR 0.907, 95% CI 0.646-1.274; one-sided stratified P = 0.287). The median (95% CI) OS was 12.7 (10.2-14.9) months with axitinib/ BSC and 9.7 (5.9-11.8) months with placebo/BSC ( Figure 1A ). Prespecified subgroup analyses indicated no significant differences in OS between treatment arms regardless of geographic region or baseline tumour invasion ( Figure 2 ). In an exploratory subgroup analysis, however, a positive trend for better OS with axitinib/BSC was observed in some subgroups, such as ECOG PS 1, excluding patients intolerant to prior antiangiogenic therapy, and baseline α-fetoprotein ≥400 ng/ml ( Figure 2) . Notably, when patients who were intolerant to prior therapy were excluded, the difference in OS showed an improvement for axitinib/BSC (n = 121) over placebo/BSC (n = 51) [HR 0.622; P = 0.013; median: 12.3 (95% CI 9.5-14.0) versus 9.2 (95% CI 4.3-10.0) months, respectively] (supplementary Figure S2A , available at Annals of Oncology online). In the Cox proportional hazards analysis, several baseline characteristics [ECOG PS, vascular invasion, prior therapy, Barcelona Clinic Liver Cancer staging, and trial outcome index (TOI) score (physical and functional well-being +HepCS-18)] were associated with OS; however, upon adjusting for these factors, treatment effect was consistent with the primary analysis (HR 0.811, P = 0.238).
PFS was longer with axitinib/BSC than placebo/BSC [HR 0.618; P = 0.004; median: 3.6 (95% CI 2.3-4.6) versus 1.9 (95% CI 1.9-3.5) months; Figure 1B ]. In prespecified subgroup analyses, PFS was significantly better with axitinib/BSC among patients at Asian, but not non-Asian, sites (supplementary Figure S2B /C, available at Annals of Oncology online). Similarly, a longer PFS with axitinib/BSC than placebo/BSC (P = 0.001) was observed among patients with, but not without, baseline tumour invasion. In the axitinib/BSC versus placebo/BSC arm, respectively, TTP was significantly longer (HR 0.621; P = 0.006; median 3.7 versus 1.9 months) and CBR was higher (31.3% versus 11.8%; P = 0.003), whereas the difference in ORR did not reach statistical significance (9.7% versus 2.9%; P = 0.091) (supplementary Table S1 , available at Annals of Oncology online). The time to deterioration, based on the composite end point of death, tumour progression, or FHSI-8 mean score decrease ≥3 points, whichever occurred first, was 1.9 months in both arms (supplementary Text, available at Annals of Oncology online).
safety
More than 90% of patients in each arm reported all-causality, allgrade AEs (Table 2 ). Common AEs with axitinib/BSC included diarrhoea, hypertension, and decreased appetite. A higher percentage of axitinib/BSC-treated than placebo/BSC-treated patients experienced grade ≥3 AEs, particularly hypertension, diarrhoea, and hand-foot skin reaction. Serious AEs were also higher with axitinib/BSC than placebo/BSC (47% versus 24%). Grade 3 laboratory abnormalities were generally more prevalent with axitinib/BSC than placebo/BSC, but the incidence of grade 4 laboratory abnormalities was low in both arms. Sixteen (12%) axitinib/BSC-treated patients died on study (within 28 days after the last dose of study medication) due to disease progression (n = 13) or AE ( pneumonia, liver failure, or septicaemia; n = 1 each). Eight (12%) placebo/BSC-treated patients died due to disease progression (n = 6) or AE (acute renal and liver failure or obstructive airway disorder; n = 1 each). AE-related treatment discontinuations (29% versus 13%), dose reductions (35% versus 7%), or temporary discontinuations (65% versus 25%) occurred more frequently with axitinib/BSC versus placebo/BSC. Axitinib/BSC treatment did not lead to increased incidence of haemorrhage (18% versus 16% with placebo/BSC) and arterial thromboembolic events, gastrointestinal perforation, and venous thromboembolic disorders were low (1% each).
serum soluble protein biomarkers
Baseline specimens from 181 patients were included in the analysis (detailed results in supplementary text, available at Annals of Oncology online). Based on the unstratified log-rank test, low baseline serum level of E-selectin or stromal cell-derived factor (SDF)-1 were associated with significantly improved OS among patients treated with axitinib/BSC compared with placebo/BSC, suggesting their predictive potential. The Cox proportional hazards model identified lower than the median baseline levels of interleukin (IL)-6, E-selectin, IL-8, angiopoietin-2, migration inhibitory factor (MIF), or c-MET as potential positive prognostic factors for HCC (P unadjusted ≤ 0.009 or lower).
In the axitinib/BSC arm, patients who achieved a clinical benefit had mean or median baseline serum levels of IL-6 and angiopoeitin-2 that were 50% and 35%, respectively, lower than 
discussion
This study, which compared axitinib/BSC and placebo/BSC in second-line HCC, failed to meet the primary end point. Prespecified subgroup analyses did not reveal OS benefit of axitinib/BSC either, although an exploratory subgroup analysis suggested improved OS when patients intolerant to first-line antiangiogenic therapy were excluded. However, the study demonstrated improvements in PFS, TTP, and CBR with axitinib/BSC over placebo/BSC. Furthermore, the study showed the acceptable safety profile of axitinib/BSC in advanced HCC, consistent with the known safety profile of axitinib. PROs generally favoured placebo/BSC, which could be explained by more frequent treatment-related AEs experienced by axitinib/BSCtreated patients, and time to deterioration was the same in both arms. The absence of improvement in time to symptomatic progression, albeit OS benefit, has been reported for sorafenib in previous phase III trials [3, 4] . Because of a seemingly early separation in the OS curve, survival data from this study were further analysed, but the outcomes confirmed the primary results (supplementary Text, available at Annals of Oncology online). A failure to detect OS differences between treatment arms might indicate inadequate activity of axitinib in advanced HCC, unlike advanced renal cell carcinoma, but also could be explained by factors such as slight imbalance in baseline patient characteristics and/or post-study treatments (33.6% of axitinib/BSC-treated patients versus 54.4% of placebo/BSC-treated patients received follow-up treatments). With regard to patient characteristics, other second-line treatment studies evaluating survival in patients with HCC following first-line sorafenib therapy reported that patients who discontinued sorafenib due to AEs or entered the second-line clinical trials had better prognosis, leading to a longer OS, than those who discontinued sorafenib due to tumour or liver disease progression or those who were ineligible, respectively, and that tumour progression pattern was associated with post first-line survival [12] [13] [14] . In our study, more patients (25%) in the placebo/BSC arm were intolerant to first-line therapy than in the axitinib/BSC arm (10%), which might explain improved OS with axitinib/BSC over placebo/BSC when intolerant patients were excluded from the analysis. Although patients were stratified by the presence or absence of extrahepatic spread and/or vascular invasion, it still remains possible that some imbalance existed between the two treatment arms with regard to the proportion of patients with different tumour progression pattern. It should also be noted that the median OS observed with the placebo/BSC arm (9.7 months) in this study was longer than the anticipated 5 months, as well as the 7.6 and 8.2 months reported for placebo/BSC in second-line HCC from phase III studies [15, 16] . Plausible reasons for longer than anticipated OS include frequent post-study treatments, selection of patients with more favourable prognosis (as explained above; also exclusion of patients with main portal vein invasion by HCC), and/or improved quality of BSC for patients with HCC in recent years. These findings point to the importance of selecting more appropriate patient eligibility criteria and stratification factor(s) in designing second-line clinical trials in advanced HCC. Patients in the axitinib/BSC arm achieved longer PFS (P = 0.004) and TTP (P = 0.006), and higher CBR (P = 0.003) compared with those in the placebo/BSC arm. Furthermore, these improvements were preferentially seen among patients from Asian, but not non-Asian, sites. It is unclear whether such regional disparities reflect differences in pathophysiology, genetic components, and/or in clinical practice standards in different regions.
McNamara et al. [17] recently reported promising clinical activity of axitinib as second-line therapy for HCC in a single-arm, open-label phase II study. The study met its primary end point (>20% tumour control). Although the median PFS (3.6 months) was the same as in the current study, the median OS of 7.1 months was shorter than either treatment arm reported here, which might be due to more patients with advanced stages of disease enrolling in the McNamara study. The results of the current study are in line with outcomes reported in randomized phase III studies of other antiangiogenic agents for treatment of second-line HCC. The REACH trial reported lack of OS advantage (HR 0.866; P = 0.1391) for ramucirumab, a monoclonal anti-VEGFR-2 antibody [15] . Ramucirumab/BSC, however, provided significantly improved PFS and ORR over placebo/BSC. Furthermore, the study revealed potential predictive value of baseline α-fetoprotein, which was also observed here. In the BRISK-PS study, addition of brivanib, a dual inhibitor of VEGFR and fibroblast growth factor receptor, to BSC produced similarly disappointing OS results, although TTP and ORR were better in patients with sorafenib-refractory/intolerant HCC [16] . HCC is a complex disease of multifactorial causes, including viral infections, alcohol-related liver cirrhosis, and genetic alterations, and often occurs in the setting of chronic liver disease. Studies investigating biomarkers for tumour progression would facilitate understanding of molecular mechanisms involved in HCC pathogenesis. This study confirmed the previously reported prognostic association between lower baseline levels of circulating IL-6 or angiopoeitin-2 and longer OS in advanced HCC [18] , and additionally identified proteins involved in immune cell mechanisms (E-selectin, IL-8, and MIF) and cell survival pathways (c-MET) as potential prognostic markers. The study also suggested possible predictive value of E-selectin and SDF-1. The association between low baseline serum SDF-1 and longer OS in axitinib/BSC-treated patients is especially compelling for metastatic potential via SDF-1/CXCR4 interaction. Low activation levels of SDF-1/CXCR4 pathway favouring clinical benefit in axitinib/BSC-treated patients may point towards strategies for patient selection.
In conclusion, axitinib/BSC did not improve OS over placebo/ BSC, but resulted in longer PFS and TTP, and higher CBR, with an acceptable safety profile in patients with advanced HCC previously treated with antiangiogenic therapy. The potential prognostic and predictive biomarkers identified in this study may warrant further investigation.
